t
AOTI, Inc. held its Annual General Meeting on 21 May 2026. All 12 resolutions presented to shareholders were passed on a poll, consisting of 11 ordinary resolutions and 1 special resolution. Of the 106,359,163 ordinary shares in issue, the special resolution was approved with 99.80% of votes cast for it.
| Date | 21 May 2026 |
| Time | 11:15:36 |
| Category | AGMs and other meetings |
| ID | 3000F |
21 May 2026
AOTI, Inc. (the "Company" or "Group" or "AOTI")
Result of Annual General Meeting
The Annual General Meeting of AOTI, Inc. was held at the offices of Burges Salmon, 6 New St Square, London, EC4A 3BF on 21 May 2026 at 10:00 a.m.
All 12 resolutions put to members were passed on a poll. Resolutions 1 to 11 were passed as ordinary resolutions and Resolution 12 was passed as a special resolution.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To receive the Company's annual report and accounts for the year ended 31 December 2025, together with the Directors' and Auditor's Report thereon. |
71,546,968 |
100.00 |
0 |
0.00 |
891,488 |
|
Resolution 2 (Ordinary) To approve the Directors' Remuneration Report for the year ended 31 December 2025. |
72,290,728 |
99.80 |
147,728 |
0.20 |
0 |
|
Resolution 3 (Ordinary) To approve the Directors' Remuneration Policy for the year ended 31 December 2025. |
72,290,728 |
99.80 |
147,728 |
0.20 |
0 |
|
Resolution 4 (Ordinary) To re-appoint Douglas Le Fort as a director of the Company. |
71,564,669 |
98.79 |
873,787 |
1.21 |
0 |
|
Resolution 5 (Ordinary) To re-appoint Michael Griffiths as a director of the Company. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 6 (Ordinary) To re-appoint Anthony Bourne as a director of the Company. |
72,290,728 |
99.80 |
147,728 |
0.20 |
0 |
|
Resolution 7 (Ordinary) To re-appoint Richard Cotton as a director of the Company. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 8 (Ordinary) To re-appoint Ceri Morgan as a director of the Company. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 9 (Ordinary) To re-appoint Jayesh Pankhania as a director of the Company. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 10 (Ordinary) To re-appoint Grant Thornton (Ireland) as auditor of the Company. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 11 (Ordinary) To authorise the Directors to determine the fees payable to the auditor. |
72,438,456 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 12 (Special) To disapply statutory pre-emption rights for the purpose of financing or refinancing a transaction. |
72,290,728 |
99.80 |
147,728 |
0.20 |
0 |
As at 21 May 2026, there were 106,359,163 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
ENDS
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
|
Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden
|
+44 (0)20 3100 2000
|
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins
|
+44 (0)20 3727 1000
|
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent. reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net